Drug Profile

Research programme: Anti-NLRP3-ASC antibodies - AC immune

Latest Information Update: 28 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AC Immune
Class Anti-inflammatories; Antibodies
Mechanism of Action NLRP3 protein inhibitors; PYCARD protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Neurodegenerative disorders

Most Recent Events

28 Jul 2024 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Switzerland
23 Mar 2021 Pharmacodynamics data from a preclinical studies in Neurodegenerative disorders released by AC Immune
23 Mar 2021 AC Immune plans in vivo proof-of-concept studies for Neurodegenerative disorders in the quarter IV of 2021

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com